Positive Impact (PI) has announced that it is now the exclusive UK distributor for InflammaDry, an in-practice test to aid the diagnosis of dry eye in just four easy steps.
InflammaDry is said by PI to be the first and only, rapid, in-practice test which detects MMP-9, a biomarker for inflammation that is consistently elevated in the tears of patients with dry eye disease.
Commenting on the announcement, joint managing director of PI, Nick Atkins, said: “We are delighted to be able to make this unique diagnostic tool available to UK dry eye practitioners in both optometry and ophthalmology.”
Mr Atkins added: “All other dry eye tests measure tear production and stability. InflammaDry recognises elevated levels of MMP-9 to identify patients that may otherwise be missed with other dry eye testing methods.”
He concluded: “This is a reliable and relatively low cost disposable test that is simple to use and gives a definitive result in just 10 minutes.”